The overall goal of this Specialized Resource is to provide state-of-the-art high-resolution imaging, quantitative image analysis and modeling, surgery and pathology expertise to the main and developmental Projects. In addition, the Resource serves as an innovative facility to further develop and validate new cancer imaging approaches required in the different projects. Whole body and microscopic intravital imaging in live animals will be essential in establishing imaging-phenotype correlations, in validating targets and linked biomarkers, and in assessing efficacy of therapeutic agents. Surgical expertise is essential to all projects for chamber preparations, orthotopic tumor implantations, exteriorization of organs for imaging and physiologic monitoring during prolonged imaging sessions. Pathology services includes guidance and supervision in necropsy and tissue harvesting, tissue imaging, histopathologic review of tissues within pathophysiologic context and performing advanced immunohistochemistry. The Resource will continue to provide stability to the overall program and allow the investigators to focus on biological aspects and efficiently address critical issues relevant to the goals of this ICIMIC. Added benefits of this Resource are the high level of quality control, consistency of protocols and efficient cross-referencing of imaging results from different projects, high level maintenance of all equipment, 24/7 access to all imaging systems. The Resource also plays a critical role in training of junior staff (through the Career Development Program), fellows and graduate students.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA086355-15
Application #
8693592
Study Section
Special Emphasis Panel (ZCA1-SRLB-9)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
15
Fiscal Year
2014
Total Cost
$77,684
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Iaconelli, Jonathan; Lalonde, Jasmin; Watmuff, Bradley et al. (2017) Lysine Deacetylation by HDAC6 Regulates the Kinase Activity of AKT in Human Neural Progenitor Cells. ACS Chem Biol 12:2139-2148
Arlauckas, Sean P; Garris, Christopher S; Kohler, Rainer H et al. (2017) In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. Sci Transl Med 9:
Miller, Miles A; Weissleder, Ralph (2017) Imaging the pharmacology of nanomaterials by intravital microscopy: Toward understanding their biological behavior. Adv Drug Deliv Rev 113:61-86
Engblom, Camilla; Pfirschke, Christina; Zilionis, Rapolas et al. (2017) Osteoblasts remotely supply lung tumors with cancer-promoting SiglecFhigh neutrophils. Science 358:
Miller, Miles A; Askevold, Bjorn; Mikula, Hannes et al. (2017) Nano-palladium is a cellular catalyst for in vivo chemistry. Nat Commun 8:15906
Dubach, J Matthew; Kim, Eunha; Yang, Katherine et al. (2017) Quantitating drug-target engagement in single cells in vitro and in vivo. Nat Chem Biol 13:168-173
Vinegoni, Claudio; Fumene Feruglio, Paolo; Brand, Christian et al. (2017) Measurement of drug-target engagement in live cells by two-photon fluorescence anisotropy imaging. Nat Protoc 12:1472-1497
Pucci, Ferdinando; Garris, Christopher; Lai, Charles P et al. (2016) SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactions. Science 352:242-6
Roy, Jeremy; Kim, Bongki; Hill, Eric et al. (2016) Tyrosine kinase-mediated axial motility of basal cells revealed by intravital imaging. Nat Commun 7:10666
Pfirschke, Christina; Engblom, Camilla; Rickelt, Steffen et al. (2016) Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. Immunity 44:343-54

Showing the most recent 10 out of 316 publications